Immune response elicited in the tumor microenvironment upon rMV‐SLAMblind cancer virotherapy
Cancer Science · 2023-05 · 114 (5) · 2158-2168
DOI: 10.1111/cas.15740 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 22.02.2023. Verfasst von Kanako Moritoh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Oncolytic Viruses, Oncolytic Virotherapy, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health and Labour Sciences Research Grants, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Oncolytic virotherapy is a promising therapy for cancer. We previously established a recombinant measles virus (rMV‐SLAMblind) that targets NECTIN4‐expressing cancer cells and demonstrated its antitumor effects using a xenograft model in an immunodeficient mouse. In the current study, to investigate the immune response after rMV‐SLAMblind therapy, we developed an immunocompetent cancer mouse model by introducing the NECTIN4 gene into mouse cancer cell lines. NECTIN4‐expressing mouse cancer cells were successfully killed by rMV‐SLAMblind in vitro. After transplantation of the NECTIN4‐expressing tumor cells, rMV‐SLAMblind significantly suppressed tumor growth in immunocompetent mice. Thus, this immunocompetent mouse cancer model could be a powerful tool in which to study the effect of rMV‐SLAMblind therapy on the immune response. Using this model we found that rMV‐SLAMblind elicited significant activation of natural killer cells, type 1 helper T cells and the tumor‐specific CD8 + T‐cell response in the tumor microenvironment. Immune cell depletion study revealed that CD8 + cells particularly played significant roles in the therapeutic efficacy of rMV‐SLAMblind. Thus, rMV‐SLAMblind exerts a therapeutic effect, not only directly by tumor cell killing, but also indirectly by efficient induction of antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Chieko Kai
Förderung
- Health and Labour Sciences Research Grants
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Moritoh, K., Shoji, K., Amagai, Y., Fujiyuki, T., Sato, H., Yoneda, M., & Kai, C. (2023). Immune response elicited in the tumor microenvironment upon rMV‐SLAMblind cancer virotherapy. Cancer Science, 114(5), 2158-2168. https://doi.org/10.1111/cas.15740
Vancouver
Moritoh K, Shoji K, Amagai Y, Fujiyuki T, Sato H, Yoneda M, et al. Immune response elicited in the tumor microenvironment upon rMV‐SLAMblind cancer virotherapy. Cancer Science. 2023;114(5):2158-2168. doi:10.1111/cas.15740
BibTeX
@article{Moritoh2023,
author = {Moritoh, Kanako and Shoji, Koichiro and Amagai, Yosuke and Fujiyuki, Tomoko and Sato, Hiroki and Yoneda, Misako and Kai, Chieko},
title = {Immune response elicited in the tumor microenvironment upon rMV‐SLAMblind cancer virotherapy},
journal = {Cancer Science},
year = {2023},
volume = {114},
number = {5},
pages = {2158--2168},
doi = {10.1111/cas.15740}
}
EUVIMED